Alternative splicing is an important mechanism behind KAI1 loss of function in breast cancer patients from Saudi Arabia

Tetraspanin CD82 Correlates with and May Regulate S100A7 Expression in Oral Cancer

“…KAI1 is another name for CD82. Truncated KAI1 or alternatively spliced (AS) KAI1 is associated with invasive metastasis and poor patient outcomes—except when (AS) KAI1 is expressed at low levels in human bladder cancers [ 1 , 21 , 55 ]. Unlike the wild-type CD82, the truncated KAI1 can be detected by the TS82b antibody but not the Abcam EPR4112 antibody.…”

“…The TS82b antibody targets the extracellular loop, while the EPR4112 antibody targets the C-terminal intracellular domain of the protein. That is, the truncated KAI1 lacks an intact C-terminus [ 21 ]. We used an ab66400 anti-CD82 antibody that is similar to the Abcam EPR4112 antibody but with a known epitope sequence corresponding to human CD82 amino acid 250 to the C-terminus.…”

“…Therefore, the 37-50 kDa CD82 in CAL 27 is N-glycosylated, rejecting our hypothesis. Next, we tested if the CD82 protein in CAL 27 is a wild type CD82 protein or if it is a truncated CD82 that lacks an intact C-terminus [21]. Our data demonstrated that although both TS82b and Abcam ab66400 anti-CD82 antibodies could detect the 75-100 kDa CD82 protein band, only the TS82b antibody could detect the 37-50 kDa CD82 protein band; the Abcam ab66400 anti-CD82 antibody was not able to detect the 37-50 kDa CD82 protein band (with or without PNGase F treatment).…”

Investigations of a Possible Role of SNPs in KAI1 Gene on Its Down-Regulation in Breast Cancer

“…Immunohistochemical KAI1 expression profile of cancer and control samples in the study, has been retrieved from our previous study (Kussaibi et al, 2019) which has been performed on FFPE tumor and control samples' paraffin sections (3-4μm thick), on Ventana Ultraview Autostainer using Ventana DAB detection universal kit (Ventana, Tucson, AZ, USA) following the standard protocol with further optimization, using as primary antibody (anti-CD82 TS82b, Abcam, Cambridge, UK). The antibody expression level of each sample was classified into: partial, diffuse or no expression.…”

“…In a previous study, we investigated the expression level of KAI1 by immunohistochemistry from breast cancer tissue and none-neoplastic breast tissues using anti-CD82 TS82B (Kussaibi et al, 2019). Out of 59 tumor samples included in the current study, 35% (n=22/59) showed expression of KAI1 protein (partial or diffuse).…”